All In MedTech

Device Trial Radar · NCT03674892

Intranasal Neurostimulation in Ameliorating Symptoms of Neuropathic Corneal Pain

Assessing the Efficacy of Intranasal Neurostimulation in Ameliorating Symptoms of Neuropathic Corneal Pain

Last checked: Nov 19, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

21

Actual

Start

Sep 28, 2018

Primary completion

Sep 9, 2022

Study completion Sep 9, 2023

Sponsor

Lead sponsor
Tufts Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 18, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, interventional, open-label, single arm, non-randomized trial treating 30 patients with peripheral or mixed neuropathic corneal pain at their baseline exam and following 45 days and 90 days of daily use with the TrueTear™ ITN device.

Conditions

  • Cornea

Interventions

  • TrueTear™ intranasal neurostimulator (ITN)Device

    TrueTear™ intranasal neurostimulator (ITN)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change to Overall Pain by the Visual Analogue Scale (VAS) After Intranasal Neurostimulator (ITN) Stimulation at BaselineTime frame: immediately before and after ITN on Day 1 (baseline)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tufts Medical Center

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.